Tyrosine kinase inhibitor (TKI) for the management of advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)‐sensitizing mutations has been established in the first‐line setting, which has become the treatment paradigm for certain EGFR aberrations including exon 19 deletions and exon 21 L858R mutations.1, 2. Here, EGFR is linked to lung cancer.